close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Avilar Therapeutics

News headline image
Avilar Therapeutics to Showcase Preclinical Data on sFlt1 ATAC Degrader for the Treatment of Preeclampsia
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Names Leslie Meltzer, Ph.D. as Chief Executive Officer
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular Protein Degrader Platform at the American Association of Immunologists Annual Meeting
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Receives U.S. Patent for Novel Extracellular Protein Degraders
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders at Targeted Protein Degradation Summit
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present at Upcoming Industry Conferences
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Presents New In Vivo Non-Human Primate Data for ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present In Vivo Non-Human Primate Data on ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present New In Vivo Proof-of-Concept Data for ATAC Extracellular Protein Degraders at Upcoming Drug Discovery Conferences
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Announces Formation of Scientific Advisory Board With Leading Experts in Protein Degradation, Chemistry, Genetics, and Drug Discovery
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Executives to be Featured Speakers on Advances in Protein Degradation at Upcoming Drug Discovery Conferences
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present Scientific Poster on ATACs, a New Class of Degraders for Targeting Extracellular Proteins, at Protein Degradation Conference
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics to Present at the Guggenheim Targeted Protein Degrader Day
From Avilar Therapeutics
Via Business Wire
News headline image
Avilar Therapeutics Launches With $60 Million Seed Financing to Pioneer Extracellular Protein Degradation
From Avilar Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.